MRVI Q2 2022 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$243M+11.5% YoY

Gross Profit

$205M84.6% margin

Operating Income

$181M74.4% margin

Net Income

$71M29.3% margin

EPS (Diluted)

$1.28

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

$164M

Free Cash Flow

$163M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.4B

Stockholders' Equity

$457M

Cash & Equivalents

$551M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$243M	$218M	+11.5%
Gross Profit	$205M	$180M	+14.0%
Operating Income	$181M	$154M	+17.7%
Net Income	$71M	$49M	+45.0%

Revenue Segments

Nucleic Acid Production Segment

$225M93%

Biologics Safety Testing Segment

$17M7%